Loading the procedure…
Loading the procedure…
Medicare volume, surgeons, state markets and device makers
Balloon sinuplasty and functional endoscopic sinus surgery. Main billing specialty: otolaryngology.
Medicare fee-for-service sinus surgery & balloon dilation cases in the 50 states summed: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 5% on average (231 state-years, 2020–2024): a close guide.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 131 | 15,296−0.9%/yr | −0.9%/yr | 4.61.1× | 88% | 19,700 in 2030+4.3%/yr |
| Texas | 145 | 15,144−1.2%/yr | −1.2%/yr | 7.11.6× | 92% | 18,900 in 2030+3.8%/yr |
| Florida | 144 | 14,5270%/yr | 0%/yr | 6.61.5× | 92% | 19,700 in 2030+5.2%/yr |
| New York | 61 | 6,979−3.8%/yr | −3.8%/yr | 3.90.9× | 89% | 7,410 in 2030+1%/yr |
| Arizona | 46 | 6,368+5.8%/yr | +5.8%/yr | 8.72.0× | 93% | 7,720 in 2030+3.3%/yr |
| Illinois | 41 | 5,453+5.6%/yr | +5.6%/yr | 4.00.9× | 88% | 8,180 in 2030+7%/yr |
| Pennsylvania | 51 | 5,134−4.5%/yr | −4.5%/yr | 3.80.9× | 58% | 5,170 in 2030+0.1%/yr |
| Georgia | 44 | 4,459−4%/yr | −4%/yr | 5.21.2× | 88% | 4,620 in 2030+0.6%/yr |
| North Carolina | 39 | 3,683−8.4%/yr | −8.4%/yr | 3.80.9× | 87% | 4,040 in 2030+1.6%/yr |
| Ohio | 27 | 3,442−2.1%/yr | −2.1%/yr | 3.20.7× | 67% | 3,940 in 2030+2.3%/yr |
| Tennessee | 40 | 3,324+0.1%/yr | +0.1%/yr | 4.81.1× | 84% | 4,300 in 2030+4.4%/yr |
| New Jersey | 22 | 3,263+0.4%/yr | +0.4%/yr | 3.10.7× | 94% | 4,190 in 2030+4.2%/yr |
| South Carolina | 33 | 3,194−0.9%/yr | −0.9%/yr | 4.71.1× | 86% | 4,830 in 2030+7.1%/yr |
| Alabama | 30 | 3,147−2.3%/yr | −2.3%/yr | 7.31.7× | 85% | 3,630 in 2030+2.4%/yr |
| Virginia | 23 | 2,887−4.8%/yr | −4.8%/yr | 2.80.6× | 80% | 2,650 in 2030−1.4%/yr |
| Indiana | 33 | 2,791−11%/yr | −11%/yr | 4.00.9× | 88% | 2,910 in 2030+0.7%/yr |
| Kansas | 30 | 2,753+4.9%/yr | +4.9%/yr | 6.91.6× | 81% | 4,320 in 2030+7.8%/yr |
| Washington | 24 | 2,704+1.8%/yr | +1.8%/yr | 3.60.8× | 77% | 3,880 in 2030+6.2%/yr |
| Wisconsin | 14 | 2,675+8.3%/yr | +8.3%/yr | 4.81.1× | 79% | 4,240 in 2030+8%/yr |
| Massachusetts | 25 | 2,622−3.9%/yr | −3.9%/yr | 2.80.6× | 53% | 3,080 in 2030+2.7%/yr |
| Louisiana | 31 | 2,414−5.1%/yr | −5.1%/yr | 6.01.4× | 73% | 2,260 in 2030−1.1%/yr |
| Maryland | 29 | 2,344−4.8%/yr | −4.8%/yr | 2.70.6× | 95% | 1,970 in 2030−2.8%/yr |
| Missouri | 24 | 2,268−7.2%/yr | −7.2%/yr | 3.70.8× | 88% | 2,500 in 2030+1.7%/yr |
| Oklahoma | 17 | 2,185+7.6%/yr | +7.6%/yr | 4.51.0× | 69% | 3,570 in 2030+8.5%/yr |
| Nevada | 14 | 2,106−0.8%/yr | −0.8%/yr | 7.41.7× | 95% | 2,330 in 2030+1.7%/yr |
| Michigan | 14 | 2,062−11%/yr | −11%/yr | 2.50.6× | 64% | 1,990 in 2030−0.6%/yr |
| Colorado | 19 | 2,002−1.7%/yr | −1.7%/yr | 4.20.9× | 85% | 2,650 in 2030+4.8%/yr |
| Mississippi | 20 | 1,659−6.5%/yr | −6.5%/yr | 4.51.0× | 91% | 1,580 in 2030−0.9%/yr |
| Minnesota | 14 | 1,403−0.1%/yr | −0.1%/yr | 3.10.7× | 92% | 2,620 in 2030+11%/yr |
| Oregon | 13 | 1,298−4.4%/yr | −4.4%/yr | 3.10.7× | 88% | 1,460 in 2030+2%/yr |
| Connecticut | 10 | 1,256−2.8%/yr | −2.8%/yr | 3.80.9× | 97% | 1,730 in 2030+5.5%/yr |
| Kentucky | 10 | 1,177−7.5%/yr | −7.5%/yr | 2.60.6× | 88% | 1,340 in 2030+2.2%/yr |
| Nebraska | 19 | 1,127−1.5%/yr | −1.5%/yr | 4.41.0× | 82% | 1,010 in 2030−1.8%/yr |
| Iowa | 11 | 1,050−4.1%/yr | −4.1%/yr | 2.40.5× | 89% | 1,110 in 2030+1%/yr |
| Utah | 10 | 862−3.8%/yr | −3.8%/yr | 4.00.9× | 83% | 1,410 in 2030+8.5%/yr |
| Idaho | 5 | 636+0.2%/yr | +0.2%/yr | 3.20.7× | 67% | 930 in 2030+6.5%/yr |
| Arkansas | 7 | 620−8.4%/yr | −8.4%/yr | 1.70.4× | 69% | 890 in 2030+6.2%/yr |
| Montana | 5 | 522+4.6%/yr | +4.6%/yr | 2.80.6× | 73% | 730 in 2030+5.7%/yr |
| Delaware | 6 | 435−5.7%/yr | −5.7%/yr | 2.60.6× | 88% | 480 in 2030+1.7%/yr |
| South Dakota | 5 | 319−11%/yr | −11%/yr | 2.50.6× | 48% | 1,110 in 2030+23%/yr |
| Hawaii | 4 | 276−3.9%/yr | −3.9%/yr | 2.20.5× | 78% | 340 in 2030+3.4%/yr |
| Maine | 4 | 254−3.5%/yr | −3.5%/yr | 1.60.4× | 0% | 510 in 2030+12%/yr |
| New Hampshire | 1 | 250−0.6%/yr | −0.6%/yr | 1.10.3× | 45% | 340 in 2030+5.2%/yr |
| District of Columbia | 3 | 234−13%/yr | −13%/yr | 3.80.9× | 98% | 250 in 2030+0.9%/yr |
| West Virginia | 1 | 228−14%/yr | −14%/yr | 1.10.3× | 55% | 150 in 2030−6.5%/yr |
| New Mexico | 2 | 212−18%/yr | −18%/yr | 0.90.2× | 72% | 280 in 2030+4.7%/yr |
| Wyoming | 2 | 188−4.4%/yr | −4.4%/yr | 1.70.4× | 100% | 260 in 2030+5.3%/yr |
| Alaska | 1 | 183−1%/yr | −1%/yr | 1.50.3× | 100% | 340 in 2030+11%/yr |
| North Dakota | 1 | 132−10%/yr | −10%/yr | 1.30.3× | 16% | 180 in 2030+5.1%/yr |
| Rhode Island | 0 | 108−12%/yr | −12%/yr | 1.20.3× | 59% | 90 in 2030−3.1%/yr |
Professional codes (what the surgeon bills): CPT 31295, 31296, 31297, 31298, 31255, 31267, 31276, 31287, 31288, 31237.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed, summed over the states listed: states MedaRep covers where the procedure tops 100 Medicare cases a year. All Medicare adds Medicare Advantage patients at each state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. How the numbers are made · Data sources
In the last 10 years FDA made 37 decisions (510(k) clearances, De Novo grants, PMA approvals and supplements) under this category’s product codes, held by 1 company. The most active:
| Company | Decisions, 10 years |
|---|---|
| Medtronic | 37 |
Product codes: OWO (drug-eluting sinus stent). A company whose devices for this procedure are filed under other codes is not counted, and a PMA supplement counts as a decision of its own. Applicants are rolled up to their parent company.
The competitive landscape: each company scored on innovation pace, recall and report signals, commercial momentum and financial capacity.
Across the covered states the share outside the hospital has moved +3 pts since 2019, to 86%.
The 10 busiest do 33% of the cases CMS names in California; 64 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Procedure | Surgeons | Medicare FFS | Growth since 2019 | Forecast |
|---|---|---|---|---|
| Ear tubes & middle ear surgery | 69 | 8,303−6.6%/yr | −6.6%/yr | 8,360 in 2030+0.1%/yr |
| Sleep apnea & airway implants | 151 | 5,383+26%/yr | +26%/yr | 5,940 in 2030+1.6%/yr |
| Cochlear implants | 114 | 3,948+5.5%/yr | +5.5%/yr | 5,240 in 2030+4.8%/yr |
Every procedure · Markets by state · Device companies · Compare two states
In 2025, 11 companies reported engagement with surgeons in the covered states worth $972K in consulting, speaking, meals and travel tied to these products, about $745 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 3 clearances and approvals in the category.
Which surgeons each company engages, and the dollars reported, are in the state rankings. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.